Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dalton Receives Notice of Award from NIDA of NIH to Fund Research

Published: Friday, September 06, 2013
Last Updated: Friday, September 06, 2013
Bookmark and Share
The goal of the research work is to identify and establish candidates for further development towards a future drug product.

Dalton Medicinal Chemistry has received notice of award from the National Institute On Drug Abuse (NIDA) to research and discover a novel series of compounds with the potential to treat drug abuse and alleviate pain.

This work will be supported by NIDA of the National Institutes of Health (NIH) under Award Number R21DA036251 which includes funding for the project.

Dalton Medicinal Chemistry will utilize their proprietary knowledge and expertise to design, synthesize and test several novel classes of compounds for these applications.

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: “It is exceptionally exciting to receive notice of this competitive award from National Institute On Drug Abuse (NIDA) which germinated from the creative insights of the talented scientists at Dalton. We are delighted to have the opportunity to initiate and conduct this important research.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,400+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dalton Receives Compliant Rating From Health Canada
The rating resulted from a Good Manufacturing Practices (GMP) inspection conducted at Dalton’s facility during March 2016.
Friday, May 27, 2016
Dalton Announces Manufacturing and Development Agreement with RLPC
Drug development and manufacturing contract to support toxicology studies for VR23.
Thursday, July 16, 2015
Dalton Pharma Services Announces Manufacturing Agreement with Andes Biotechnologies
New service contract to supply large molecule sterile dose manufacturing services for their Phase I/II clinical trials.
Friday, June 12, 2015
Dalton Pharma Services Expands Sterile Powder Manufacturing Capabilities
Addition of a high-speed automated sterile powder filling line.
Thursday, January 29, 2015
Dalton Supports Client Milestone in Dengue Treatment Clinical Trial
Completes API development and manufacture for Phase I trial.
Tuesday, August 07, 2012
Scientific News
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!